Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Receivables (2020 - 2022)

Historic Receivables for Tango Therapeutics (TNGX) over the last 3 years, with Q4 2022 value amounting to $2.0 million.

  • Tango Therapeutics' Receivables changed 0.0% to $2.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $2.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $2.0 million for FY2022, which is 0.0% changed from last year.
  • Tango Therapeutics' Receivables amounted to $2.0 million in Q4 2022, which was down 0.0% from $2.0 million recorded in Q3 2022.
  • Tango Therapeutics' 5-year Receivables high stood at $8.0 million for Q3 2021, and its period low was $2.0 million during Q4 2020.
  • For the 3-year period, Tango Therapeutics' Receivables averaged around $2.9 million, with its median value being $2.0 million (2020).
  • Per our database at Business Quant, Tango Therapeutics' Receivables changed by 0.0% in 2021 and then plummeted by 7500.0% in 2022.
  • Tango Therapeutics' Receivables (Quarter) stood at $2.0 million in 2020, then changed by 0.0% to $2.0 million in 2021, then changed by 0.0% to $2.0 million in 2022.
  • Its last three reported values are $2.0 million in Q4 2022, $2.0 million for Q3 2022, and $2.0 million during Q2 2022.